Regulus Therapeutics Inc (RGLS) Actualités

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit PR...

Form 8-K - Current report

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical...

Form 8-K - Current report

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates

Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates PR...

Form 8-K - Current report

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference

Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference PR Newswire SAN...

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference PR...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities